Peptidoglycan D,D-transpeptidase MrdA · SINGLE PROTEIN · Bacteria
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Peptidoglycan D,D-transpeptidase MrdA shows approved-linked disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P0AD65. Start with bacterial disease, then reuse UniProt P0AD65 as the stable protein anchor across project notes and exports.
Start with bacterial disease, then reuse UniProt P0AD65 as the stable protein anchor across project notes and exports.
Peptidoglycan D,D-transpeptidase MrdA shows approved-linked disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include AMDINOCILLIN, AMDINOCILLIN PIVOXIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPeptidoglycan D,D-transpeptidase MrdA
Review this target as Peptidoglycan D,D-transpeptidase MrdA, mapped to UniProt P0AD65. Sequence length is 633 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peptidoglycan D,D-transpeptidase MrdA as ChEMBL target CHEMBL2354313, mapped to UniProt P0AD65. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Peptidoglycan D,D-transpeptidase MrdA is the right protein anchor across sources, using UniProt P0AD65 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why bacterial disease is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Peptidoglycan D,D-transpeptidase MrdA |
| Target Type | SINGLE PROTEIN |
| Organism | Bacteria |
| UniProt | P0AD65 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Peptidoglycan D,D-transpeptidase MrdA |
| UniProt Accession | P0AD65 |
| Component Type | Protein |
| Sequence Length | 633 aa |
Peptidoglycan D,D-transpeptidase MrdA
Review this target as Peptidoglycan D,D-transpeptidase MrdA, mapped to UniProt P0AD65. Sequence length is 633 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Peptidoglycan D,D-transpeptidase MrdA shows approved-linked disease relevance led by bacterial disease. 1 more disease program remain visible in the same review block.
Start review with bacterial disease because it currently carries approved-linked support. Linked drugs include AMDINOCILLIN, AMDINOCILLIN PIVOXIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.